2024/12/01 by Marin Vander Schaaf, Kyrle Luth, Danyelle M. Townsend +5
Medicine · Pharmacology, Toxicology and Pharmaceutics · #Pharmaceutical studies and practices #Pharmacogenetics and Drug Metabolism #Pharmacological Effects and Toxicity Studies
paper · pdf · doi:10.1007/s00044-024-03360-7
openalex publication_date 2024/12/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Abstract Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme involved in the Phase I metabolism of numerous medications used in clinical practice. Its potential significance in pediatric pharmacotherapy is underscored by the unique metabolic profile of children, which differs markedly from adults, especially in neonates, infants, and young children due to developmental changes in enzyme activity. This review explores the critical role of CYP3A4 in the metabolism of drugs used in the pediatric population, with a particular focus on combination drug therapies. Given the high potential for drug-drug interactions in combination therapies, understanding the modulation of CYP3A4 activity is essential for optimizing therapeutic outcomes and minimizing adverse effects. This paper further examines the structural similarities between these medications and bergamottin, a known CYP3A4 inhibitor found in citric fruits such as grapefruit. Variability in CYP3A4 activity, influenced by genetic polymorphisms, developmental stage, and external factors, necessitates careful consideration in the prescribing and management of drugs in children. This review corroborates the need for personalized medicine approaches and enhanced pharmacovigilance to ensure the safe and effective use of CYP3A4-metabolized drugs in the pediatric population. Graphical Abstract